Profile data is unavailable for this security.
About the company
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-8.35m
- Incorporated2014
- Employees13.00
- LocationBiodexa Pharmaceuticals PLC1 Caspian Point, Caspian WayABINGDON CF10 4DQUnited KingdomGBR
- Phone+44 123 584 1575
- Websitehttps://www.biodexapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Windtree Therapeutics Inc | 0.00 | -48.83m | 386.98k | 14.00 | -- | -- | -- | -- | -8.38 | -8.38 | 0.00 | -0.3449 | 0.00 | -- | -- | 0.00 | -172.27 | -48.72 | -791.65 | -52.57 | -- | -- | -- | -- | -- | -- | 22.36 | -- | -- | -- | 72.96 | -- | -42.51 | -- |
| Regenerative Medical Technology Grop Inc | 5.04m | -7.06m | 394.17k | 1.00 | -- | -- | -- | 0.0782 | -0.5629 | -0.5629 | 0.4019 | -2.40 | 1.30 | 24.95 | 69.50 | -- | -182.18 | -177.25 | -- | -- | 59.76 | 64.83 | -140.06 | -465.06 | 0.0784 | -0.0279 | -- | -- | 70.44 | 167.30 | 43.31 | -- | -- | -- |
| Health Advance Inc | -100.00bn | -100.00bn | 405.70k | 3.00 | -- | 0.0166 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -9.17m | 424.72k | 22.00 | -- | 0.2607 | -- | -- | -557.54 | -557.54 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -245.96 | -65.13 | -417.51 | -73.82 | -- | -- | -- | -- | -- | -5.25 | 0.0606 | -- | -- | -- | 73.04 | -- | -- | -- |
| Novelstem International Corp | 3.00k | 2.31m | 468.81k | 15.00 | 0.2079 | -- | -- | 156.27 | 0.0481 | 0.0481 | 0.00006 | -0.0438 | 0.0281 | -- | 0.80 | -- | 630.69 | -- | -- | -- | -- | -- | 22,424.33 | -- | -- | -- | -- | -- | 0.00 | -- | 22.79 | -- | -- | -- |
| Longevity Health Holdings Inc | 1.46m | -5.74m | 499.06k | 15.00 | -- | -- | -- | 0.3425 | -5.22 | -5.22 | 1.26 | -2.23 | 0.5077 | 1.11 | 47.31 | 97,153.34 | -199.84 | -- | -- | -- | 57.86 | -- | -393.63 | -- | 0.2676 | -- | -- | -- | -- | -- | 36.91 | -- | -- | -- |
| Helix BioMedix Inc | 2.07m | -2.58m | 609.46k | 8.00 | -- | 0.3887 | -- | 0.295 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| Biodexa Pharmaceuticals PLC-ADR | 0.00 | -8.35m | 625.72k | 13.00 | -- | 0.0041 | -- | -- | -691.70 | -691.70 | 0.00 | 247.45 | 0.00 | -- | -- | 0.00 | -43.26 | -78.06 | -54.55 | -109.39 | -- | -- | -- | -2,404.45 | -- | -- | 0.042 | -- | -100.00 | -- | 19.07 | -- | 19.40 | -- |
| Bio Path Holdings Inc | 0.00 | -11.18m | 635.86k | 10.00 | -- | -- | -- | -- | -1.71 | -1.71 | 0.00 | -0.866 | 0.00 | -- | -- | 0.00 | -611.66 | -81.00 | -- | -90.58 | -- | -- | -- | -- | -- | -65.76 | -- | -- | -- | -- | 38.46 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 389.79k | -5.33m | 716.69k | 5.00 | -- | 0.4818 | -- | 1.84 | -2.41 | -2.41 | 0.1286 | 0.3219 | 0.1729 | -- | 25.08 | 77,958.00 | -236.36 | -101.93 | -336.65 | -125.09 | -- | -- | -1,367.34 | -592.18 | -- | -- | 0.00 | -- | 19.29 | -5.04 | -8.60 | -- | -- | -- |
| Avenue Therapeutics Inc | 1.40m | -3.74m | 783.12k | 2.00 | -- | 0.2202 | -- | 0.5578 | -1.55 | -1.55 | 0.50 | 1.12 | 0.4422 | -- | -- | 702,000.00 | -119.06 | -159.81 | -122.59 | -215.40 | -- | -- | -269.23 | -- | -- | -- | 0.00 | -- | -- | -- | -12.29 | -- | -- | -- |
| THC Farmaceuticals Inc | 7.58k | -60.45k | 797.79k | 2.00 | -- | 0.3118 | -- | 105.25 | -0.0036 | -0.0036 | 0.0005 | 0.1411 | -- | -- | -- | 3,790.00 | -- | -- | -- | -- | 100.00 | -- | -1,591.69 | -- | -- | -- | 0.2051 | -- | 348.43 | -- | 5,170.19 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -49.19m | 810.34k | 8.00 | -- | -- | -- | -- | -175.56 | -175.56 | 0.00 | -3.04 | 0.00 | -- | -- | 0.00 | -282.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -52.12 | -- | -- | -- |
| Aditxt Inc | 5.95k | -42.24m | 853.38k | 26.00 | -- | -- | -- | 143.43 | -13,234.74 | -13,234.74 | 0.3444 | -151.86 | 0.0003 | 1.54 | 0.0304 | 228.85 | -207.03 | -148.78 | -- | -279.11 | -1,134.96 | -- | -724,419.70 | -8,283.15 | 0.02 | -12.48 | -- | -- | -79.23 | -- | -23.40 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Biodexa Pharmaceuticals PLC's reporting currency: US Dollar USD
44.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Dec 2025 | 190.66k | 27.96% |
| Armistice Capital LLCas of 31 Dec 2025 | 100.00k | 14.67% |
| HRT Financial LPas of 31 Dec 2025 | 10.58k | 1.55% |
| UBS Securities LLCas of 31 Dec 2025 | 1.92k | 0.28% |
| GAMMA Investing LLCas of 31 Dec 2025 | 1.78k | 0.26% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 183.00 | 0.03% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 101.00 | 0.02% |
| Hilton Head Capital Partners LLCas of 31 Dec 2025 | 30.00 | 0.00% |
| RhumbLine Advisers LPas of 31 Dec 2025 | 24.00 | 0.00% |
| Brio Capital Management LLCas of 14 Nov 2024 | 2.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
